Last reviewed · How we verify
Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation
Approved treatments
- Vanflyta · Daiichi Sankyo Inc
Vanflyta works by blocking the macrophage colony-stimulating factor 1 receptor, which is involved in the growth and survival of cancer cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation patent landscape — cliff calendar, originator estates, attackable patents
- Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation treatment landscape brief
- Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation treatment updates RSS
Frequently asked questions about Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation
What drugs treat Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation?
Tracked treatments include Vanflyta.
What is the treatment for Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation?
Standard treatment for Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation includes Vanflyta. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation patent cliff · Acute myeloid leukemia with FMS-like tyrosine kinase-3 mutation CI report
- Treatment: Vanflyta · Daiichi Sankyo Inc
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing